ARGX Quote, Financials, Valuation and Earnings

Biodexa Pharmaceuticals PLC has a net margin of 15.95% compared to argenx SE's net margin of --. argenx SE's return on equity of 21.33% beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.

argenx SE has a consensus price target of $763.30, signalling upside risk potential of 28.62%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.97 which suggests that it could grow by 1302.45%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than argenx SE, analysts believe Biodexa Pharmaceuticals PLC is more attractive than argenx SE.

argenx SE has a beta of 0.593, which suggesting that the stock is 40.713% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.489, suggesting its more volatile than the S&P 500 by 48.943%.

argenx SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. argenx SE pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.

argenx SE quarterly revenues are $738.4M, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. argenx SE's net income of $774.2M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, argenx SE's price-to-earnings ratio is 46.69x while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for argenx SE is 17.01x versus 1.16x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

Koninklijke Philips NV has a net margin of 15.95% compared to argenx SE's net margin of -6.64%. argenx SE's return on equity of 21.33% beat Koninklijke Philips NV's return on equity of -5.84%.

argenx SE has a consensus price target of $763.30, signalling upside risk potential of 28.62%. On the other hand Koninklijke Philips NV has an analysts' consensus of $33.00 which suggests that it could grow by 28.46%. Given that argenx SE has higher upside potential than Koninklijke Philips NV, analysts believe argenx SE is more attractive than Koninklijke Philips NV.

argenx SE has a beta of 0.593, which suggesting that the stock is 40.713% less volatile than S&P 500. In comparison Koninklijke Philips NV has a beta of 0.778, suggesting its less volatile than the S&P 500 by 22.205%.

argenx SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Koninklijke Philips NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. argenx SE pays -- of its earnings as a dividend. Koninklijke Philips NV pays out -0.14% of its earnings as a dividend.

argenx SE quarterly revenues are $738.4M, which are smaller than Koninklijke Philips NV quarterly revenues of $5.4B. argenx SE's net income of $774.2M is higher than Koninklijke Philips NV's net income of -$357.1M. Notably, argenx SE's price-to-earnings ratio is 46.69x while Koninklijke Philips NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for argenx SE is 17.01x versus 1.25x for Koninklijke Philips NV. Usually stocks with elevated PS ratios are considered overvalued.

ProQR Therapeutics NV has a net margin of 15.95% compared to argenx SE's net margin of -216.04%. argenx SE's return on equity of 21.33% beat ProQR Therapeutics NV's return on equity of -62.97%.

argenx SE has a consensus price target of $763.30, signalling upside risk potential of 28.62%. On the other hand ProQR Therapeutics NV has an analysts' consensus of $9.71 which suggests that it could grow by 579.32%. Given that ProQR Therapeutics NV has higher upside potential than argenx SE, analysts believe ProQR Therapeutics NV is more attractive than argenx SE.

argenx SE has a beta of 0.593, which suggesting that the stock is 40.713% less volatile than S&P 500. In comparison ProQR Therapeutics NV has a beta of 0.244, suggesting its less volatile than the S&P 500 by 75.592%.

argenx SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProQR Therapeutics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. argenx SE pays -- of its earnings as a dividend. ProQR Therapeutics NV pays out -- of its earnings as a dividend.

argenx SE quarterly revenues are $738.4M, which are larger than ProQR Therapeutics NV quarterly revenues of $4.6M. argenx SE's net income of $774.2M is higher than ProQR Therapeutics NV's net income of -$9.9M. Notably, argenx SE's price-to-earnings ratio is 46.69x while ProQR Therapeutics NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for argenx SE is 17.01x versus 6.02x for ProQR Therapeutics NV. Usually stocks with elevated PS ratios are considered overvalued.

uniQure NV has a net margin of 15.95% compared to argenx SE's net margin of -1403.2%. argenx SE's return on equity of 21.33% beat uniQure NV's return on equity of -239.27%.

argenx SE has a consensus price target of $763.30, signalling upside risk potential of 28.62%. On the other hand uniQure NV has an analysts' consensus of $35.67 which suggests that it could grow by 174.65%. Given that uniQure NV has higher upside potential than argenx SE, analysts believe uniQure NV is more attractive than argenx SE.

argenx SE has a beta of 0.593, which suggesting that the stock is 40.713% less volatile than S&P 500. In comparison uniQure NV has a beta of 0.364, suggesting its less volatile than the S&P 500 by 63.568%.

argenx SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. uniQure NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. argenx SE pays -- of its earnings as a dividend. uniQure NV pays out -- of its earnings as a dividend.

argenx SE quarterly revenues are $738.4M, which are larger than uniQure NV quarterly revenues of $5.2M. argenx SE's net income of $774.2M is higher than uniQure NV's net income of -$73.3M. Notably, argenx SE's price-to-earnings ratio is 46.69x while uniQure NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for argenx SE is 17.01x versus 23.54x for uniQure NV. Usually stocks with elevated PS ratios are considered overvalued.